Grove Bank & Trust’s Acadia Pharmaceuticals ACAD Stock Holding History

Grove Bank & Trust’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.06K	Hold	200	–	–	﹤0.01%	722
2026 Q1	$4.45K	Hold	200	–	–	﹤0.01%	718
2025 Q4	$5.34K	Hold	200	–	–	﹤0.01%	713
2025 Q3	$4.27K	Hold	200	–	–	﹤0.01%	727
2025 Q2	$4.31K	Hold	200	–	–	﹤0.01%	713
2025 Q1	$3.32K	Hold	200	–	–	﹤0.01%	724
2024 Q4	$3.67K	Hold	200	–	–	﹤0.01%	628
2024 Q3	$3.08K	Hold	200	–	–	﹤0.01%	614
2024 Q2	$3.25K	Hold	200	–	–	﹤0.01%	532
2024 Q1	$3.7K	Hold	200	–	–	﹤0.01%	542
2023 Q4	$6.26K	Hold	200	–	–	﹤0.01%	517
2023 Q3	$4.17K	Hold	200	–	–	﹤0.01%	589
2023 Q2	$4.79K	Hold	200	–	–	﹤0.01%	549
2023 Q1	$3.76K	Hold	200	–	–	﹤0.01%	590
2022 Q4	$3K	Buy	+200	New	+$3.13K	﹤0.01%	554

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Grove Bank & Trust's ACAD Position: Q2 2026 in Review

Grove Bank & Trust held its Acadia Pharmaceuticals (ACAD) position steady in Q2 2026 at 200 shares worth $5.06K. The position accounts for ﹤0.01% of the portfolio, ranked #722.

Grove Bank & Trust first reported a position in ACAD in Q4 2022 and has held it in 15 quarters since. The position peaked at $6.26K in Q4 2023. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

Grove Bank & Trust held 200 shares of Acadia Pharmaceuticals worth $5.06K as of Q2 2026.
Grove Bank & Trust left its Acadia Pharmaceuticals share count unchanged in Q2 2026.
Acadia Pharmaceuticals made up ﹤0.01% of Grove Bank & Trust's portfolio in Q2 2026, its #722 holding.
Grove Bank & Trust first reported a position in Acadia Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
Grove Bank & Trust's Acadia Pharmaceuticals position peaked at $6.26K in Q4 2023.
354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Grove Bank & Trust's 13F filing for Q2 2026, filed 7 Jul 2026.